Motor and non-motor symptoms are managed through a variety of pharmacological treatments that include dopamine-based therapies for PD motor symptoms (e.g., levodopa, dopamine agonists) and nondopaminergic approaches (e.g., cholinesterase inhibitors, selective serotonin reuptake inhibitors) for nonmotor manifestations of PD. The gene discussed is BCHE; the disease is Parkinson disease.